How This Works
Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis[1][6]. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, suggesting cytoprotective effects[2]. Such ultrashort peptides are known to influence cell differentiation, proliferation, and apoptosis via gene regulation[3]. Additionally, EDL has been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site[7].
References
MDPI International Journal of Molecular Sciences
— Transport of biologically active ultrashort peptides using POT and LAT carriers
PubMed — Advances in Gerontology
— Tripeptides slow down aging process in renal cell culture (Khavinson et al., 2014)
Nature — Signal Transduction and Targeted Research
— Research peptides: current applications and future directions (Li et al., 2022)
Sigma-Aldrich
— Peptide Handling and Storage Guide (aliquoting, freeze–thaw, labeling)
Bachem
— Handling and Storage Guidelines for Peptides (temperature, stability)
PubMed — Biochemistry
— HIV-1 protease inhibitors: enthalpic versus entropic optimization of binding affinity
PubMed — Biochemistry
— HIV-1 protease inhibitors Glu-Asp-Leu and Glu-Asp-Phe: thermodynamic studies (Velazquez-Campoy & Freire, 2000)
NCBI Bookshelf — WHO
— Best practices for measurements and related procedures (asepsis, preparation, preparation)
CDC
— Vaccine preparation: route (angle/site guidance)
CDC (Subcut Measurement PDF)
— Technique diagram and site guidance for measurements
